cyrilzakka/clinical-trials huggingface dataset:
NIH Release/Relock Socket

The goal of the research is to create and evaluate a new technology for management of daily residual limb fluid volume fluctuation.

Limb fluid volume changes that can occur in the residual limb of a lower-limb amputee can result in changes in socket fit that lead to discomfort, skin injuries, and reduced mobility. It is known that limb fluid volume fluctuations can be reduced for some people by intermittently removing (doffing) the socket throughout the day. It is believed that partially doffing the socket may have a similar benefit, and could be made more convenient thereby promoting easier compliance for prosthetic users.

The goal of the research is to create and evaluate a new technology for management of daily residual limb fluid volume fluctuation. The technology enables partial doffing through the release and relock of a socket panel and the prosthetic pin used to hold the limb in place. The expected outcomes are an enhanced understanding of how socket adjustments after activity facilitate limb fluid volume recovery, subsequent fluid retention, and improved socket fit.

Eligibility Criteria:
Inclusion Criteria:

* Had trans-tibial amputation at least 18 months prior to enrollment
* Regularly wear a definitive prosthesis for at least 7 hours per week
* Have a residual limb length of at least 9 cm
* K2 or higher MFCL
* Able to walk continuously with a prosthesis for at least 2 minutes at a time
* Sit, stand, and negotiate a step of 5.0 cm

Participants involved remotely will have to meet the following inclusion criteria:

* Have a spare prosthesis
* No cognitive issues
* Good hand dexterity and strength (not frail)
* Capable of communication over a video Zoom conference call.

Exclusion Criteria:

* Current presence of skin breakdown
* Unable to satisfy inclusion criteria
Abdominal Nerve Blockade in Chronic Heart Failure.

Patients with chronic heart failure and undergoing right heart catheterization will be enrolled in this study. Subjects will undergo catheterization of the heart to obtain central cardiac pressure and other cardiac hemodynamic parameters. Subsequently, the subject will undergo a regional nerve block of the splanchnic nerves.

This study will be a prospective, uncontrolled clinical trial. The study will not be controlled as invasive monitoring of hemodynamics will be performed, allowing clear demonstration of a cause-effect relationship. The goal of the study is to provide proof of concept.

Patients will undergo detailed physiological testing.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of heart failure (HF)
* Symptomatic with dyspnea
* On a stable HF drug regimen

Exclusion Criteria:

* Ongoing treatment with oral anticoagulation other than aspirin
* Immunosuppressive medications for solid organ transplant
* Acute MI (STEMI or Type I NSTEMI) within 7 days
* Systolic blood pressure \< 90 mmHg or \>180 mmHg
* Infiltrative cardiomyopathy or constrictive cardiomyopathy
* Chronic kidney disease stage 5
* Pregnancy
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease

The purpose of this study is to assess whether Apremilast is safe and effective in the treatment of patients with Behcet Disease.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of Behçet Disease. At the time of diagnosis, subjects must meet the international study group criteria for Behçet Disease
* Females of childbearing potential (FCBP) must have negative pregnancy tests and agree to use two forms of contraception throughout the study.
* Males must use barrier contraception (latex condoms) when engaging in reproductive sexual activity with FCBP
* Laboratory criteria: Hgb ≥ 9 g/dL, WBC count ≥ 3000 /microL and ≤14,000/microL, platelet count ≥ 100,000 /microL,, serum creatinine ≤ 1.5 mg/dL (≤ 132.6 μmol/L), total bilirubin ≤ 2.0 mg/dL, AST and ALT ≤ 1.5 X ULN
* Two or more oral ulcers over the 28 day period before screening, with or without current treatment
* Two or more oral ulcers at the time of randomization (Visit 2, Baseline)

Exclusion Criteria:

* Pregnant or breast feeding
* Any condition which places the subject at risk
* Systemic fungal infection
* History of TB infection within 3 years
* History of recurrent bacterial infection
* Mycobacterium TB as indicated by a positive PPD skin test
* History of incompletely treated Mycobacterium tuberculosis
* Clinically significant chest x-ray abnormality at screening.
* Clinically significant ECG abnormality at screening
* History of HIV infection
* History of congenital or acquired immunodeficiency
* Hepatitis B surface antigen positive or Hepatitis B core antibody positive at screening
* Antibodies to Hepatitis C at screening
* History of malignancy (except for treated basal-cell skin carcinomas \> 3 years prior to screening)
* Any active major organ involvement of Behçet Disease
* Use of concomitant immune modulating therapy or topical corticosteroids.
* Use of ocular corticosteroids
* Use of any investigational medication within 4 weeks prior to randomization or 5 PK/PD half-lives (whichever is longer)
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

The purpose of the Connect™ Chronic Lymphocytic Leukemia (CLL) Disease Registry is to explore the history and real world management of patients diagnosed with CLL, provide insight into the management of CLL, and evaluate the effectiveness of first, second and subsequent therapeutic strategies employed in both the community and academic settings.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis with CLL
* Clinical decision made to initiate first-line therapy, second-line therapy or subsequent line of therapy prior to enrollment into the ConnectTM CLL registry, but within 2 months of enrollment
* Age≥18 years
* Willing and able to provide signed informed consent
* Willing and able to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel

Exclusion Criteria:

* Participation in a clinical study in which study treatment is blinded
* Patient condition is considered terminal (i.e.\<6 months to live)
Morbimortality in Older Patients Undergoing Urgent Abdominal Surgery

Morbimortality in older patients undergoing abdominal surgery.

The aim of this study is to validate the modified CriSTAL tool for 30 mortality in elderly patients undergoing urgent abdominal surgery. To provide a new tool that could be used in conjunction with clinical judgment to aid in decision-making.

The second objective of our study was to assess the quality of life, frailty, functional status and nutritional status in elderly patients that survive six months after an urgent abdominal surgery.

Eligibility Criteria:
Inclusion Criteria:

* \>65 years old, accepted in emergency department

Exclusion Criteria:

* not sign the consent
Comparison of Sleep Study Results After Partial Intracapsular Tonsillectomy Versus Total Tonsillectomy

The purpose of this study is to demonstrate similar improvements in sleep-disordered breathing as determined by sleep study with microdebrider-assisted partial intracapsular tonsillectomy and adenoidectomy versus total Bovie electrocautery tonsillectomy and adenoidectomy.

Objectives: To demonstrate similar improvement in sleep-disordered breathing as determined by polysomnography (PSG) with microdebrider-assisted partial intracapsular tonsillectomy and adenoidectomy (PITA) versus Bovie electrocautery complete tonsillectomy and adenoidectomy (T\&A).

Methods: In a retrospective cohort study children found to have Obstructive Sleep Apnea (OSA) by PSG who have undergone either PITA or T\&A as treatment will be evaluated with repeat PSG. The groups will be matched by age, sex, and severity of pre-operative Apnea-Hypopnea Indices (AHI). The investigators performing and evaluating the PSG will be blinded to type of procedure and preoperative AHI. Change scores will be computed for each participant and the change scores of the groups compared.

Eligibility Criteria:
Inclusion Criteria:

* The medical records of 149 children who underwent partial intracapsular tonsillectomy and adenoidectomy at the State University of New York (SUNY) Downstate Medical Center or the Long Island College Hospital will be reviewed to identify children with positive preoperative polysomnography. 18 of those with positive preoperative studies will be randomly selected and offered participation in the study.
* Once enrolled, the participants will be matched by age, sex, time since procedure and polysomnography results (Apnea Hypopnea Index Index within 5) to 18 children who underwent traditional tonsillectomy and adenoidectomy (out of a total of 455 patients).

Exclusion Criteria:

* Recurrent tonsillitis
* Craniofacial syndromes
* Neuromuscular disorders
* Sickle cell disease
Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications

1. i-gel
2. C-LMA

Compare the effect on gastroeosephageal reflux Postoperative complicatios.

120 ASA I-II adult patients. Patients were randomised into two groups

1. i-gel
2. C-LMA Volume controlled ventilation, general anesthesia Asses Gastroeosephageal reflux, sore throat, coughing, dysphagia,dysphonia recorded.

Eligibility Criteria:
Inclusion Criteria:

* ASA I-II
* Adult
* Elective surgery
* Bladder tumour
* Prostat hyperplasi

Exclusion Criteria:

* Emergency surgery
* Hiatal hernia
* Gastroeosephageal reflux disease
Obstructive Sleep Apnea in Obese Children and Teenagers - Occurrence and Importance of Intervention

The prevalence of childhood obesity has increased at an alarming rate over the last decades, both globally and in Denmark. There are a number of serious sequelae related to obesity, such as hypertension, hypercholesterolemia, fatty liver and prediabetes. Obesity is found to be a risk factor for obstructive sleep apnea (OSA). OSA in childhood is known to be associated with cardiovascular complications, neurocognitive problems and reduced quality of life. The correlation between obesity and OSA is still poorly understood. Early detection and intervention is of great importance as the health consequences related to OSA as well as obesity are severe. Adenotonsillectomy is recommended as first-line therapy in children with OSA. However, only around 25% of obese children benefit from this treatment compared to around 75% of normal-weight children suggesting that there might be other structural factors predisposing to OSA in obese children.

In this study the investigators aim to clarify the impact of obesity in the development of OSA. The prevalence of OSA in obese children will be investigated. Furthermore the purpose is to assess the effect of weight loss on OSA.


Eligibility Criteria:
Inclusion Criteria:

* Age: 7-18 years
* BMI \> 90th percentile for age and gender

Exclusion Criteria:

* Neuromuscular disorders
* Craniofacial syndromes / malformations
* Laryngeal and tracheal malformations
User Evaluation of the Peristomal Skin Condition in Ostomates Using ConvaTec Moldable Technology™

The primary aim of this study is to demonstrate the maintenance of healthy peri-stomal skin over a two month period in subjects who use ConvaTec Moldable Technology™ Skin Barriers as part of their standard protocol of care following surgery.


Eligibility Criteria:
Inclusion Criteria:

* Subjects who are 18 years old and older.
* Subjects who agree to participate in the evaluation and who have signed the informed consent form.
* Subjects presenting with a stoma (ileostomy, colostomy or urostomy).
* Subjects for whom ConvaTec Moldable Technology™ per package insert, within the context of routine clinical care is used as the first long-term (within 7 days of ostomy surgery) system following surgery and who have intact peristomal skin (healthy or SACs L1).

Exclusion Criteria:

* Subjects who, according to the investigator, have cognitive problems that prevent them from answering a questionnaire or for whom the evaluation could be a problem.
* Subjects who are in a simultaneous clinical evaluation.
PAI-1 Expression in Non-scarring Hair Loss

This study will investigate whether subjects who suffer from hair loss have increased levels of PAI-1 compared to age-matched control subjects. The level of PAI-1 expression will be determined in subjects without hair loss and in subjects with non-scarring hair loss, including androgenetic alopecia, telogen effluvium and alopecia areata.

This study will compare the levels of PAI-1 expression in subjects with different forms of non-scarring hair loss and in these subjects vs normal age-matched controls. Hair loss subjects will have their Northwestern Memorial Hospital and Northwestern Medical Faculty Foundation medical records reviewed to ensure they meet inclusion and exclusion criteria. All subjects will have a 4 mm punch biopsy on the scalp. Tissue PAI-1 levels from scalp skin biopsies will be determined by immunohistochemical staining. Samples will be kept for approximately 15 years, after which time unused samples will be destroyed.

Eligibility Criteria:
Inclusion Criteria:

* Age-matched control subjects who do not have a history of hair loss
* A clinical and pathologic diagnosis of androgenetic alopecia, telogen effluvium, alopecia areata or normal scalp skin
* All subjects must have given signed, informed consent prior to registration in study

Exclusion Criteria:

* History of previous hair transplantation
* Current and past use of medications topically on the scalp
* Clinical or pathologic diagnosis of a scarring alopecia
* History of inflammatory conditions of the scalp such as psoriasis
the Efficacy of Ginger Powder as an Analgesic for Intraoperative and Post- Endodontic Pain Management

The aim of the study is to evaluate the analgesic effect of ginger powder capsules compared to placebo on intra-operative and post-operative pain of single-visit endodontic treatment of mandibular molars with symptomatic irreversible pulpitis.

The pharmacological pain management usually includes administration of systemic analgesics, anti-inflammatory drugs, or antibiotics drugs. The inhibition of the inflammatory process is one of the methods to reduce or prevent pain during and after treatment.

Ginger has a lengthy history of use as a herbal medicine. Ginger has been used in traditional Chinese and Indian medicine to treat a variety of diseases, including arthritis, stomachaches, diarrhea, nausea, asthma, and respiratory problems. It was discovered that ginger also contains substances that prevent PG production. This discovery gave its anti-inflammatory benefits a solid scientific justification. Following research, it was discovered that some of the components of ginger share pharmacological traits with a novel family of dual-acting NSAIDs. These substances have significantly fewer adverse effects than traditional NSAIDs and can inhibit arachidonic acid metabolism via both the cyclooxygenase (COX) and lipoxygenase (LOX) pathways.

Various animal studies have shown that taking dried ginger or ginger extract orally can decrease acute inflammation. Numerous clinical studies back up the effectiveness of ginger in treating osteoarthritis, and in some instances, a noticeable decrease in knee pain has been reported. In some of these studies, it was discovered that ginger, even when used for extended amounts of time, significantly reduced pain and swelling in patients with osteoarthritis, rheumatoid arthritis, and muscular pain.

There have been no studies done to evaluate the impact of ginger powder on intra and post-endodontic pain. In order to find the effects of ginger powder capsules on pain after endodontic treatment, the current study was performed.

Eligibility Criteria:
Inclusion Criteria:

1. Patients aging between 18-45 years old.
2. Patients with mandibular molar with signs and symptoms of symptomatic irreversible pulpitis.
3. Systemically- healthy patients (ASA I or II).
4. Patients who agree to attend for recall appointments.
5. Patients who can understand pain scale and can sign the informed consent.

Exclusion Criteria:

1. Pregnant or lactating female patients.
2. Patients allergic to ginger, articaine or any other medicament material used in the study.
3. History of peptic ulceration.
4. Periapical abscess or fistula.
5. Non-restorable teeth.
6. Moderate or severe marginal periodontitis i.e. pocket probe\>3mm.
7. Patients on Aspirin, Clopidogrel, Dalteparin and Warfarin.
8. Radiographic evidence of external or internal root resorption vertical root fracture, perforation, calcification.
Effect Of Deep Breathing Exercises In Smokers

To determine the effect of deep breathing exercises on lung function in healthy smokers.

The purpose of the study to determine the effect of deep breathing exercise in smokers because deep breathing improve the lung capacity by filling the lung with the oxygen and improve the pulmonary function, it also reduce the stress and anxiety level by slowing down the pace of your whole body and therefore promote general relaxation and improve the quality of life in smokers, muscular activity or physical activity is also increased because by deep breathing maximum oxygen is reached to every muscle and they get nourish well so overall impact of deep breathing exercise is positive. Deep breathing exercise technique offered in the study are easy to learn and can be performed by everyone and everywhere safely, because there is no complex and pain full procedure. So deep breathing exercise have been proposed as a way of combating cigarette craving, improves quality of life and lung function.

Eligibility Criteria:
Inclusion Criteria:

Young male and female adults with age group of 20-30 years without any chronic complication doing smoking from past five years are included in this study as the basic purpose of the study is to determine the effects of deep breathing exercises in smokers

Exclusion Criteria:

1. Adults with pulmonary disease.
2. Acute infections
3. Any other systemic disease.
4. Chest deformity.
5. Adults with any disability.
Clinical Efficacy of Exosome in Degenerative Meniscal Injury

Comparison of intra-articular administration of synovial fluid-derived mesenchymal stem cells-derived exosomes with synovial fluid-derived mesenchymal stem cells on the same patient.

Mesenchymal stem cell-derived exosomes will be developed and patented as an advanced technology platform as an autologous treatment protocol to repair damaged cartilage tissue. The fact that this treatment is obtained from an autologous source will significantly contribute to the literature in the field of personalized therapy (personalized medicine) and will pave the way for discoveries. Experiences from clinical trials may guide the use of MSC exosomes in other tissue and cell damaged pathologies and immune pathologies or chronic inflammatory diseases.

This study was supported by a grant (1004, 20AG031) from The Scientific and Technological Research Council of Turkey (TUBITAK).

Eligibility Criteria:
Inclusion Criteria:

* Accepting the Informed Consent Form
* Degenerative meniscus damage grade 1, 2 or 3 on MRI in both right and left knees, and also the patient does not want surgical treatment
* Patients with the same degenerative meniscus grade in both knees
* Patients with ongoing pain
* Patients without a history of malignancy
* Absence of signs of unstable meniscus tear such as snagging or locking
* Patients with stage 0, 1 or 2 gonarthrosis according to Kellgren-Lawrence gonarthrosis staging
* Patients without lower extremity malalignment

Exclusion Criteria:

* Patients whose treatment method was explained and who did not accept the method
* Patients outside the working-age range
* Congenital lesion
* Patients requiring surgical treatment (e.g. bucket handle tear and locked knee)
* Active inflammatory or connective tissue disease is thought to affect the patient's pain (eg lupus, rheumatoid arthritis, fibromyalgia)
* Local or systemic infection
* Pregnant or breastfeeding women
* Active endocrine disorder that may affect the assessment of patient's pain (eg, hypothyroidism, diabetes)
* Active neurological disorder that may affect the assessment of the patient's pain (eg, peripheral neuropathy, multiple sclerosis)
* Active heart disease
* Presence of a pacemaker
* Conditions where MR-I is contraindicated
* Patients with stage 3 or 4 gonarthrosis according to Kellgren-Lawrence gonarthrosis staging
* Patients with lower extremity malalignment
* Patients with signs of unstable meniscus tear such as snagging or locking
Molecular PET Imaging and Plasma Biomarkers in Alzheimer´s Disease and Other Neurodegenerative Diseases

Multi-modal PET tracer study with the aim of studying the time course of regional deposition of tau in brain of subjects with high risk of being carriers of autosomal dominant Alzheimer´s disease and sporadic early onset and late onset Alzheimer´s disease patient (EOAD, LOAD) in tertiary memory clinic cohort in relation to MRI brain changes, plasma biomarker levels and cognitive performance.

Multi-PET /MRI studies , fluid biomarkers (CSF, plasma) analysis, neuropsychological testing is performed in subjects carriers and non-carriers of different APP, PS autosomal dominant AD mutatation. Both presymptomatic and symptomatic carriers and non-carriers are recruited (age range -30 to +15 years from first clinical symptoms). For comparison also a group of healthy eldersly as well as patients undergoing memory assessment with diagnosis of mild cognitive impairment (amyloid negative /amyloid positive) and diagnosis sporadic Alzheimer´s diases are recruited from Karolinska memory clinic and undergoing similar Multi-PET/MRI studies , fluid biomarker analysis, neuropsycholigal testing. The aim is to describe the evolution and spreading of tau in brain in Alzheimer continuum and compare with other pathological markers with aim of develop new diagnostic markers and therapeutic targets.

Eligibility Criteria:
Inclusion Criteria: a)belonging to families with known familial form of Alzheimer´s disease b) patient undergoing memory assessent at memory clinic with diagnosis mild cognitive impairment (MCI), Alzheimer´s disease c)healthy elderly cognitive normal

-

Exclusion Criteria:

cancer and other serious disease
Retinal Nerve Fibres Layers Thickness Study in Glaucomatous Patients

In this study the investigators are going to study the retinal nerve fibers layers (RNFL) modification of two groups of patients, one taking no drugs, the other taking forskolin, rutin and vitamins B1 and B2.


Eligibility Criteria:
Inclusion Criteria:

* Age (30-80 years);
* Baseline Intraocular pressure (IOP) (20-32 mmHg): average untreated Intra Ocular Pressure (IOP) for both eyes as determined from 2 to 4 visits within a 6-months period;
* Central Corneal Thickness (CCT) (475-650 µm): average of 3 different measurements from both eyes during the same visit;
* Pattern standard deviation (PSD) (0,50-3,00 dB) average of both eyes as stated on the most recent visual field index report
* Vertical Cup/Disk ratio (0,00-0,80): average of both eyes
* All these data were entered into a calculator specially designed for STAR (Scoring Tool for assessing risk) II parameter. The patients were divided into low-, moderate- and high risk groups according to the result given by the calculator.

Exclusion Criteria:

-other ocular pathologies than glaucoma